Radius Health & Menarini Group Provide Elacestrant Update |
| September 25, 2020 | September 2020 Bond Updates |
|
WALTHAM, Mass. and FLORENCE, Italy, Sept. 25, 2020 /PRNewswire/ -- Radius Health, Inc. ("Radius" or the "Company") (Nasdaq: RDUS) and the Menarini Group today announced an update on the elacestrant Phase 3 EMERALD trial. EMERALD Phase 3 Study The target enrollment milestone has been... |
| View more at: https://www.prnewswire.com:443/news-releases/radius-health--menarini-group-provide-elacestrant-update-301138118.html |
| Related News |
|